Enochian Biosciences Inc
ENOB
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.81M
Close$
Share Statistics
| Market cap | $17.81 Million |
|---|---|
| Enterprise Value | $16.06 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.06 |
| Beta | 0.94 |
| Outstanding Shares | 24,994,200 |
Return
| Return on Equity | 37.29% |
|---|---|
| Return on Assets | -36.13% |
| Return on Invested Capital | 25.98% |
Valuation & Multiples
| P/E Ratio | -0.36 |
|---|---|
| PEG | 0.37 |
| Price to Sales | - |
| Price to Book Ratio | -0.71 |
| Enterprise Value to Revenue | 308.98 |
| Enterprise Value to EBIT | -6.56 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | -0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 14, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lunai Bioworks Inc.
29 employees
CEO: David Weinstein A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.